HIV-associated lymphoma · 15 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-CODOX-M/R-IVAC Variant #05 | — | R 120 076 | — | — | — | ~2 | ~R 240 152 PFS proxy · indirect | 1 |
GMALL-R N/A - protocol Partial | — | R 93 528 | 5d | — | — | ~2 | ~R 186 783 indirect | — |
SC-EPOCH-RR Variant #01 | — | R 53 943 | 21d | — | — | ~6 | ~R 323 659 indirect | — |
R-CDOP Variant #01 | — | R 38 439 | 21d | — | — | ~6 | ~R 230 634 indirect | — |
R-CODOX-M Variant #01 | — | R 27 669 | 28d | — | — | ~3 | ~R 83 006 indirect | — |
R-CHOP Variant #08 | — | R 26 946 | 21d | ~14.4 mo | ~55.7 mo | ~6 | ~R 109 868 PFS proxy · indirect | 11 |
CODOX-M/IVAC Variant #02 | — | R 18 220 | — | — | — | ~2 | ~R 36 439 indirect | — |
dmCODOX-M/IVAC - Modified Magrath Variant #01 | — | R 18 220 | — | — | — | ~2 | ~R 36 439 indirect | — |
Stanford V Variant #01 Partial | — | R 18 121 | 28d | — | — | ~1 | ~R 18 121 PFS proxy · indirect | 1 |
EPOCH, dose-escalated Variant #01 | — | R 1 993 | 21d | — | — | ~6 | ~R 11 956 indirect | — |
R-EPOCH, dose-escalated Variant #01 | — | R 1 993 | 21d | — | — | ~8 | ~R 15 941 indirect | — |
CODOX-M Variant #02 | — | R 1 911 | — | — | — | ~3 | ~R 5 732 indirect | — |
dmCODOX-M - Modified Magrath Variant #01 | — | R 1 911 | — | — | — | ~3 | ~R 5 732 indirect | — |
m-BACOD Variant #02 Partial | — | R 1 320 | 21d | — | 7.6 mo | 11 | R 14 524 PFS proxy | 2 |
CHOP Variant #20 | — | R 835 | 21d | — | — | ~6 | ~R 5 011 PFS proxy · indirect | 1 |
15 of 15 regimens shown